H.C. Wainwright lowered the firm’s price target on Dyne Therapeutics (DYN) to $46 from $55 and keeps a Buy rating on the shares. The firm cites the competitive landscape for DYNE-101 and DYNE-251 as well as revised spending assumptions for the target cut.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Advances Clinical Programs Amid Financial Losses
- Dyne Therapeutics reports Q4 EPS (88c), consensus (91c)
- Dyne Therapeutics receives FDA Fast Track designation for DYNE-101
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz
- H.C. Wainwright keeps Buy on Dyne Therapeutics after data